Reduction by strontium of the bone marrow adiposity in mice and repression of the adipogenic commitment of multipotent C3H10T1/2 cells

Fournier, Carole; Perrier, Anthony; Thomas, Mireille; Laroche, Norbert; Dumas, Virginie; Rattner, Aline; Vico, Laurence; Guignandon, Alain

doi:10.1016/j.bone.2011.07.038

Cited by 44 publications

(34 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the same time, the efficiency of anti-adipogenic activity was dose-dependent in the treatment group. Although, studies about the anti-adipogenic effects of SrRN are still limited, similar results were observed in previous studies [11,18,19]. A study by Liet al showed that SrRN decreased the mRNA levels of PPAR-γ2, adipocyte lipid-binding protein 2, and lipoprotein lipase by RT-PCR, as well as the protein expression of PPAR-γ in western-blot analysis after one or two weeks of treatment in adipogenic medium [11].…”

Section: Discussionsupporting

confidence: 66%

“…In their study, SrRN reduced PPAR-γ2 and C/EBP-α mRNA in a dose-dependent manner without affecting RUNX2 gene expression whereas it repressed ALP mRNA. Later (day 5), PPAR-γ2 and CEBP-α mRNA remained inhibited by SrRN, preventing adipocyte lipid accumulation, while Runx2 and ALP mRNA were increased under adipogenic conditions [18]. Saidak et al explained that the age-related switch of osteoblastic to adipocytic differentiation could be antagonized by SrRN treatment via mechanisms involving NFATc/Maf and Wnt signaling [19].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Strontium ranelate-induced anti-adipocytic effects are involved in negative regulation of autophagy in rat bone marrow mesenchymal stem cells

Bai

2018

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

Purposes Strontium ranelate (SrRN) is a novel and effective anti-osteoporotic drug used to promote bone formation and restrain bone resorption. However, studies of the effects and mechanism of SrRN on adipocytic differentiation from bone marrow mesenchymal stem cells (BMMSCs) remain limited. Methods The cytoactivity of BMMSCs was analyzed by CCK-8 and annexin V-FITC/PI kit. Then the differentiation efficiency was analyzed by Oil Red O staining and western blotting. The level of autophagy was evaluated by immunofluorescence and western blotting. The autophagy inhibitor chloroquine and the selective Akt antagonist API-2 were used to study the relationship between autophagy regulation and adipocytic differentiation. Finally variations in β-catenin protein levels were also analyzed by western blotting, as were proteins related with autophagy and differentiation signaling pathways. Results SrRN had no influence on the vatility of BMMSCs (bone marrow mesenchymal stem cells) and exhibited anti-adipocytic effects in dose-dependent manner. At the early stage of adipocytic differentiation, autophagy level significantly increased and SrRN inhibited the variation tendency. Then we detected the PPAR-γ and β-catenin variation when applied with autophagy inhibitor CQ (chloroquine) and the same way, after Akt selective inhibitor applied in the test, the effect of SrRN was compromised. At last, we detected the increased phosphorylation of Akt-related pathway at 1.00 mM concentration of SrRN in comparison with the adipocytic induction. Conclusions SrRN could disturb the process of adipocytic differentiation of BMMSCs and interfere with the variation tendency of autophagy level after adipocytic induction in Akt-dependent manners.

show abstract

Section: Discussionsupporting

confidence: 66%

Section: Discussionmentioning

confidence: 99%

Strontium ranelate-induced anti-adipocytic effects are involved in negative regulation of autophagy in rat bone marrow mesenchymal stem cells

Bai

2018

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

show abstract

“…This in turn increases bone matrix mineralization by expressing of several osteoblastic markers like type I collagen, alkaline phosphatase, bone sialoprotein and osteocalcin (Marie et al, 2011). It has recently been reported that strontium enhances osteogenesis both in multipotent C3H10T1/2 cells and in bone marrow stromal cells while inhibiting adipogenesis (Fournier et al, 2012;Li et al, 2012). Studies by Reginster et al showed that postmenopausal women treated by strontium ranelate, exhibited higher OPG levels in serum, within a period of 3 months to 3 years after treatment initiation (Reginster et al, 2012) Collectively, strontium ranelate increases bone mass, mineral content, cortical thickness, and also improves trabecular and cortical micro-architecture, thereby increasing bone quality and strength in rats, ovariectomized rodents, and immobility-induced osteoporotic animal models (Ammann et al, 2004).…”

Section: Strontium Ranelatementioning

confidence: 99%

Marine Natural Products: New Avenue in Treatment of Osteoporosis

Chaugule¹,

Indap²,

Chiplunkar

2017

Front. Mar. Sci.

View full text Add to dashboard Cite

Bone metabolism is a physiological process that maintains the skeletal integrity and bone functions. Skeletal integrity is always balanced by two key cell types-bone resorbing osteoclasts and bone-forming osteoblasts. Imbalance between generation and function of osteoclasts and osteoblasts often leads to pathological conditions such as osteoporosis, osteopetrosis, Paget's disease. Osteoporosis is one of the most common age-related diseases characterized by decreased bone mineral density and microarchitectural deterioration. Current therapies are indeed effective in preventing bone loss but are also followed by side effects. Since many years, marine organisms have been considered as a good source of bioactive molecules or compounds with potential pharmaceutical properties. Marine Natural Products (MNPs) derived from various marine resources such as marine cyanobacteria, dinoflagellates, algae, sponges, soft corals, molluscs, fishes, and mangroves had shown profound effect on bone metabolism through inhibiting osteoclastogenesis and up-regulating osteoblastogenesis via modulating RANK/RANKL/OPG pathway. Amongst the pre-clinically investigated MNPs for management of osteoporosis, very few are under phase I clinical trials. This review discusses the currently available pharmacological drugs and there major health concern in osteoporosis treatment. It further gives an insight into various marine resources and marine-derived bioactive products, depicting their mechanism of action, functional role, and how these can be exploited for the treatment of osteoporosis.

show abstract

“…[45] было показа-но, что СР in vitro редуцирует экспрессию генов адипоци-тов в МСК и, следовательно, ингибирует адипогенез. Па-раллельно СР стимулирует дифференцировку МСК в ос-теобласты.…”

Section: таблицаunclassified

Pathogenesis of Osteoarthritis and Substantiation of the Use of Strontium Ranelate

Зайцева¹,

Алексеева²,

Насонов³

2014

rsp

View full text Add to dashboard Cite

Reduction by strontium of the bone marrow adiposity in mice and repression of the adipogenic commitment of multipotent C3H10T1/2 cells

Cited by 44 publications

References 47 publications

Strontium ranelate-induced anti-adipocytic effects are involved in negative regulation of autophagy in rat bone marrow mesenchymal stem cells

Strontium ranelate-induced anti-adipocytic effects are involved in negative regulation of autophagy in rat bone marrow mesenchymal stem cells

Marine Natural Products: New Avenue in Treatment of Osteoporosis

Pathogenesis of Osteoarthritis and Substantiation of the Use of Strontium Ranelate

Contact Info

Product

Resources

About